Dec 11, 2025 02:23AM
Dec 2, 2025 07:00AM
Dec 2, 2025 07:00AM
Aug 8, 2025 07:51AM
Mar 24, 2025 04:55AM
Sep 30, 2024 07:27AM
Sep 26, 2024 08:01AM Ovid Therapeutics (OVID) Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Sep 26, 2024 08:00AM
Aug 13, 2024 08:00AM
Aug 6, 2024 04:01PM
Jul 23, 2024 08:00AM
Jul 10, 2024 08:08AM
Jul 10, 2024 08:00AM
Jul 1, 2024 08:02AM Ovid Therapeutics (OVID) and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformatio
Jul 1, 2024 08:00AM
Jun 18, 2024 04:51AM
Mar 8, 2024 08:00AM
Nov 8, 2022 08:00AM
Nov 8, 2022 08:00AM
Jun 6, 2022 08:00AM
May 26, 2021 08:19AM Ovid Therapeutics (OVID) Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board
May 26, 2021 08:00AM
Apr 20, 2021 08:00AM
Mar 15, 2021 08:00AM
Mar 3, 2021 09:28AM
Dec 2, 2020 09:28AM
Dec 1, 2020 04:53PM
Dec 1, 2020 04:52PM Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
Nov 23, 2020 04:01PM
Nov 12, 2020 04:10PM
Oct 14, 2020 07:00AM
Oct 12, 2020 07:00AM
Sep 30, 2020 08:05AM
Sep 30, 2020 08:00AM
Aug 25, 2020 09:30AM Pre-Open Movers 08/25: (OVID) (GPS) (CRM) Higher; (PLCE) (POR) (PANW) Lower (more...)
Aug 10, 2020 08:00AM
Jul 23, 2020 07:00AM
Jul 13, 2020 09:00AM
Jul 13, 2020 07:02AM
Jul 13, 2020 07:00AM
Jun 19, 2020 08:03AM
Jun 19, 2020 08:00AM Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome
May 7, 2020 07:48AM
May 7, 2020 07:30AM
Mar 30, 2020 08:00AM
Mar 11, 2020 08:00AM
Jan 7, 2020 08:03AM
Jan 7, 2020 08:00AM
Sep 23, 2019 07:07AM Ovid Therapeutics (OVID) Reports Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
Sep 23, 2019 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All